Proteasome inhibition measurements: Clinical application

Clinical Chemistry

Volumn 46, Issue 5, 2000, Pages 673-683

  Lightcap, Eric S ^a   McCormack, Teresa A ^a   Pien, Christine S ^a   Chau, Vincent ^a,b   Adams, Julian ^a   Elliott, Peter J ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CHYMOTRYPSIN; LACTACYSTIN; PROTEASOME INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL; CELL LYSATE; CLINICAL TRIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MICHAELIS CONSTANT; NONHUMAN; PHASE 1 CLINICAL TRIAL; RAT;

ANIMALIA;

EID: 0034037622     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.5.673     Document Type: Article

References (35)

1. 1. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998;17:7151-60.
2. 2. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998;95:15671-6.
3. 3. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res 1999;59:2615-22.
4. 4. Campbell B, Adams J, Shin YK, Lefer AM. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 1999;31: 467-76.
5. 5. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J. Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 1999;104:294-300.
6. 6. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC. The proteasome inhibitor, PS-519, reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 2000;in press.
7. 7. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999;274: 22123-6.
8. 8. Lupas A, Baumeister W. The 20S proteasome. In: Peters JM, Harris JR and Finley D, eds. Ubiquitin and the biology of the cell. New York: Plenum Press, 1998:127-46.
9. 9. Fenteany G, Schreiber SL. Lactacystin, proteasome function, and cell fate. J Biol Chem 1998;273:8545-8.
10. 10. Elliott PJ, Adams J. Recent advances in understanding proteasome function. Curr Opin Drug Discov Dev 1999;2:484-90.
11. 11. Adams J, Behnke M, Chen S, Cruikshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8.
12. 12. Stein RL, Melandri F, Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 1996; 35:3899-908.
13. 13. Segel IH. Enzyme kinetics. Behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: John Wiley & Sons, 1975:227-31.
14. 14. Kahn MT, Wang K, Roufogalis BD. Identification and purification of a 90-kDa membrane bound endogenous inhibitor of multicatalytic proteinase from human red blood cells. Biochem Biophys Res Commun 1995;214:957-62.
15. 15. Tsubuki S, Saito Y, Kawashima S. Purification and characterization of an endogenous inhibitor specific to the Z-Leu-Leu Leu-MCA degrading activity in proteasome and its identification as heatshock protein 90. FEBS Lett 1994;344:229-33.
16. 16. Chu-Ping M, Slaughter CA, DeMartino GN. Purification and characterization of a protein inhibitor of the 20S proteasome (macropain). Biochim Biophys Acta 1992;1119:303-11.
17. 17. Li X, Gu M, Etlinger JD. Isolation and characterization of a novel endogenous inhibitor of the proteasome. Biochemistry 1991;30: 9709-15.
18. 18. Murakami K, Etlinger JD. Endogenous inhibitor of nonlysosomal high molecular weight protease and calcium-dependent protease. Proc Natl Acad Sci U S A 1986;83:7588-92.
19. 19. Kahn MT, Wang KKW, Villalobo A, Roufogalis BD. Characterization of a novel high molecular mass protein with peptidase activity purified from the human erythrocyte membrane by calmodulin affinity chromatography. J Biol Chem 1994;269:10016-21.
20. 20. McCormack TA, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Plamondon L, et al. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin β-lactone. Biochemistry 1998;37: 7792-800.
21. 21. Bone R, Shenvi AB, Kettner CA, Agard DA. Serine protease mechanism: structure of an inhibitory complex of α-lytic protease and a tightly bound peptide boronic acid. Biochemistry 1987;26: 7609-14.
22. 22. Bone R, Frank D, Kettner CA, Agard DA. Structural analysis of specificity: α-lytic protease complexes with analogues of reaction intermediates. Biochemistry 1989;28:7600-9.
23. 23. Takahashi LH, Radhakrishnan R, Rosenfield RE Jr, Meyer EF Jr. Crystallographic analysis of the inhibition of porcine pancreatic elastase by a peptidyl boronic acid: structure of a reaction intermediate. Biochemistry 1989;28:7610-7.
24. 24. Ditzel L, Stock D, Lowe J. Structural investigation of proteasome inhibition. Biol Chem 1997;378:239-47.
25. 25. Tanaka K, li K, Ichihara A, Waxman L, Goldberg AL. A high molecular weight protease in the cytosol of rat liver. I. Purification, enzymological properties, and tissue distribution. J Biol Chem 1986;261:15197-203.
26. 26. Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991;51:6677-85.
27. 27. Russell SJ, Steger KA, Johnston SA. Subcellular localization, stoichiometry, and protein levels ot 26S proteasome subunits in yeast. J Biol Chem 1999;274:21943-52.
28. 28. Segel GB, Cokelet GR, Lichtman MA. The measurement of lymphocyte volume: importance of reference particle deforrnability and counting solution tonicity. Blood 1981;57:894-9.
29. 29. Hempling HG, Thompson S, Dupre A. Osinotic properties of human lymphocyte. J Cell Physiol 1977;93:239-302.
30. 30. Hempling HG. The permeability of the lymphocyte membrane: applying a particle size analyzer and a hybrid computer to measure rapid changes in cell volume. Acta Cytol 1977;21:96-100.
31. 31. Holian A, Deutsch CJ, Holian SK, Daniele RP, Wilson DF. Lymphocyte response to phytohemagglutinin: intracellular volume and intracellular [K']. J Cell Physiol 1979;98:137-44.
32. 32. Kageyama K, Onoyama Y, Kogawa H, Goto E, Tanabe K. The maximum and minimum water content and cell volume of human erythrocytes in vitro. Biophys Chem 1989;34:79-82.
33. 33. Hung TC, Pham S, Steed DL, Webster MW, Butter DB. Alterations in erythrocyte rheology in patients with severe peripheral vascular disease: 1. Cell volume dependence of erythrocyte rigidity. Angiology 1991;42:210-7.
34. 34. Baskurt OK. Deformability of red blood cells from different species studied by resistive pulse shape analysis technique. Biorheology 1996;33:169-79.
35. 35. Groth-Vasselli B, Robinson D, Lally J, Schleich T, Farnsworth P. Morphological studies of an ion-dependent perinuclear cataract model. Exp Eye Res 1988;47:415-28.